Originally published In Press as doi:10.1074/jbc.M201661200 on April 11, 2002
J. Biol. Chem., Vol. 277, Issue 25, 23019-23027, June 21, 2002
A Short Segment of the R Domain of Cystic Fibrosis
Transmembrane Conductance Regulator Contains Channel Stimulatory
and Inhibitory Activities That Are Separable by Sequence
Modification*
Junxia
Xie
,
Lynn M.
Adams
§,
Jiying
Zhao¶,
Thomas A.
Gerken
,
Pamela B.
Davis
§**, and
Jianjie
Ma§¶
From the Departments of
Pediatrics,
Biochemistry, and § Physiology and Biophysics, Case
Western Reserve University School of Medicine, Cleveland, Ohio 44106 and the ¶ Department of Physiology and Biophysics, University of
Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical
School, Piscataway, New Jersey 08854
Received for publication, February 19, 2002, and in revised form, April 10, 2002
 |
ABSTRACT |
The regulatory (R) domain of the cystic fibrosis
transmembrane conductance regulator (CFTR) contains consensus
phosphorylation sites for cAMP-dependent protein kinase
(PKA) that are the basis for physiological regulation of the CFTR
chloride channel. A short peptide segment in the R domain with a net
negative charge of B9 (amino acids 817-838, NEG2) and predicted
helical tendency is shown to play a critical role in CFTR chloride
channel function. Deletion of NEG2 from CFTR completely eliminates the
PKA dependence of channel activity. Exogenous NEG2 peptide interacts
with CFTR to exert both stimulatory and inhibitory effects on the
channel function. The NEG2 peptide with sequence scrambled to remove
helical tendencies also inhibits channel function, but does not
stimulate. Similar results are found for a NEG2 peptide whose helical
structure is disrupted by a proline residue. When six of the negatively charged carboxylic acid residues are replaced by their cognate amides,
reducing net negative charge to B3, but increasing helical propensity
as assessed by circular dichroism, the peptide stimulates CFTR channel
function, but does not inhibit. We speculate that the NEG2 region
interacts with other cytosolic domains of CFTR to control opening and
closing transitions of the chloride channel.
 |
INTRODUCTION |
Defects in CFTR,1 a
chloride channel located in the apical membrane of epithelial cells,
are associated with the common genetic disease, cystic fibrosis (1-3).
CFTR is a 1480-amino acid protein that is a member of the ATP binding
cassette transporter family (4). The general structure of these
membrane proteins includes two membrane spanning domains, each
consisting of six transmembrane segments, and two nucleotide binding
folds (NBF1 and NBF2). Most members of the ATP binding cassette family
use the free energy of ATP hydrolysis to actively transport substrates
across the membrane (5). However, unlike the other members of this
family, CFTR contains a unique regulatory (R) domain, and encodes a
cAMP-regulated chloride channel (6-8).
The R domain of CFTR contains several consensus PKA phosphorylation
sites (9-11) that are the basis for physiological regulation of this
chloride channel. CFTR channel opening requires phosphorylation of
serine residues in the R domain, and ATP binding and hydrolysis at the
nucleotide binding folds (7, 12, 13). Phosphorylation adds negative
charges to the R domain, and introduces global conformational changes
reflected by a reduction in the
-helical content of the R domain
protein (14). Thus, electrostatic and/or allosteric changes mediated by
phosphorylation are likely responsible for interactions between the R
domain and other CFTR domains that regulate channel function (15,
16).
Rich et al. (17) showed that deletion of amino acids
708-835 from the R domain (
R-CFTR), which removes most of the PKA consensus sites, allows the CFTR chloride channel to open without phosphorylation. The open probability of
R-CFTR is one-third that of
the wild type (wt) CFTR channel and does not increase upon PKA
phosphorylation, although other biophysical properties of the channel
(i.e. conductance and anion selectivity) are similar to
wt-CFTR (18, 19). These data suggest that deletion of the R domain
removes both inhibitory and stimulatory effects conferred by the R
domain on CFTR chloride channel function. In support of this
suggestion, addition of exogenous unphosphorylated R domain protein
(amino acids 588-858) to wt-CFTR blocks the chloride channel (20, 21),
and the block is relieved if the R domain becomes phosphorylated,
indicating that the unphosphorylated R domain is inhibitory.
Conversely, exogenous phosphorylated R domain protein (amino acids
588-855 or 645-834) stimulates the
R-CFTR channel, suggesting that
the phosphorylated R domain is stimulatory (18, 19). Therefore, it
appears that the phosphorylation state of the R domain determines
whether it functions to stimulate or inhibit chloride channel activity.
In this work we identify a stretch of negatively charged amino acids at
the carboxyl terminus of the R domain (817-838, NEG2), with a net
charge of
9, which appears to be involved in both the stimulatory and
inhibitory functions of the R domain on chloride channel activity.
Furthermore, by modifying the sequence of this peptide, we were able to separate its stimulatory and inhibitory functions.
 |
EXPERIMENTAL PROCEDURES |
Subcloning of CFTR Gene--
The wt-CFTR cDNA was cloned
into an Epstein-Barr virus-based episomal eukaryotic expression vector,
pCEP4 (Invitrogen, San Diego, CA), between the NheI and
XhoI restriction sites (18, 20-22). The
NEG1 and
NEG2
deletion mutants were created using the pALTER mutagenesis system and
shuttled from pALTER into pCEP4 by substituting the corresponding
fragment in pCEP4 wt-CFTR with the mutant fragment between the
BstZ171 and XhoI restriction sites. The
NEG1-CFTR cDNA has 27 bases deleted (amino acids 725-733). The
NEG2-CFTR cDNA has 66 bases deleted (amino acids 817-838). Deletions were confirmed by sequencing across the junction site.
Expression of CFTR in HEK 293 Cells--
A human embryonic
kidney cell line (293-EBNA HEK; Invitrogen) was used for transfection
and expression of the CFTR proteins (18, 20-22). The HEK-293 cell line
contains a pCMV-EBNA vector, which constitutively expresses the
Epstein-Barr virus nuclear antigen-1 (EBNA-1) gene product and
increases the transfection efficiency of Epstein-Barr virus-based
vectors. Cells were maintained in Dulbecco's modified Eagle's medium
with 10% fetal bovine serum and 1% L-glutamine. Geneticin
(G418, 250 µg/ml) was added to the cell culture medium to maintain
selection of the cells containing the pCMV-EBNA vector. LipofectAMINE
reagent (Invitrogen) in Opti-MEM media (serum-free) was used to
transfect the HEK-293 cells with pCEP4(wt), pCEP4(
NEG1), or
pCEP4(
NEG2). After 5 h, serum was added to the media (10%
final serum concentration). Twenty-four hours after transfection, the
transfection media was replaced with fresh media. The cells were
harvested 2 days after transfection and microsomal membrane vesicles
were prepared for single channel measurements in the lipid bilayer
reconstitution system (18, 20-22).
In Vitro Phosphorylation of CFTR Proteins--
CFTR proteins
isolated in membrane vesicles were bound to protein G-agarose using a
mouse monoclonal anti-human CFTR antibody (mAb 24-1, Genzyme). The
protein G-agarose was washed and [
-32P]ATP (10 µCi)
and protein kinase A (~10 units/50 µl) was added. Samples were
incubated at 30 °C for 1 h during phosphorylation. Excess
[
-32P]ATP was removed, and SDS-PAGE sample buffer (200 mM Tris-Cl, pH 6.7, 9% SDS, 6%
-mercaptoethanol, 15%
glycerol, and 0.01% bromphenol blue) was added to denature CFTR and
release it from the protein G-agarose. The samples were subjected to
electrophoresis on a 5% SDS-polyacrylamide gel, transferred to a
polyvinylidene difluoride membrane, and exposed to film. The
phosphorylated proteins from 12.5-µl vesicles were loaded in each
lane. Densitometry was performed and normalized to CFTR protein band
intensity recorded from Western blots performed as previously described
(18, 20-22) on 10-µl vesicles for wt-CFTR and the
NEG2-CFTR
samples, and 20-µl vesicles containing
NEG1-CFTR, using the
Genzyme 24-1 monoclonal antibody developed with ECL.
Peptide Studies--
Twenty-two residue amino acid peptides
corresponding to the NEG2, NEG2i, s-NEG2, p-NEG2, and h-NEG2i sequences
were custom synthesized (Quality Controlled Biochemicals, Hopkinton,
MA) (see Table I). The NH2- and COOH-terminal residues of
each peptide were acetylated and amidated, respectively. The peptides
were determined to be >95% pure by high performance liquid
chromatography mass spectral analysis. Molecular modeling was performed
with Insight II software (MSI Inc., San Diego, CA) using standard amino acid side chain conformations. Secondary structure predictions were
made using the secondary structure consensus prediction feature of
the Network Protein Sequence analysis site at npsa-pbil.icp.fr (23,
24).
Circular dichroism (CD) spectra were obtained on a Jasco J-1810 Spectra
Polarimeter (Jasco, Easton, MD) equipped with Jasco Spectra Manager
(version 1.51.00) data acquisition software. Spectra were obtained at
4 °C from 1-mm path length quartz cells. CD spectra were the average
of eight scans collected at 0.1-nm intervals from 260 to 190 nm using
standard instrument settings. Peptide concentrations ranged between 15 and 49 µM, at pH ~ 6.7. Peptide stock solution
concentrations were obtained by quantitative amino acid analysis
performed by the Protein/Peptide Core Facility of the Massachusetts
General Hospital.
Reconstitution of CFTR Channels in Lipid Bilayer
Membranes--
Electrophysiological analysis of single channel
activity was performed as previously described (17, 21). Briefly, lipid bilayer membranes were formed across an aperture of ~200 µm
diameter with a mixture of
phosphatidylethanolamine:phosphatidylserine:cholesterol in a ratio of
5:5:1. The lipids were dissolved in decane at a concentration of 33 mg/ml. The recording solutions contained (in mM):
cis (intracellular), 200 CsCl, 1 MgCl2, 2 ATP,
and 10 HEPES-Tris (pH 7.4); and trans (extracellular),
50 CsCl, 10 HEPES-Tris (pH 7.4). Vesicles (1-4 µl) containing wt-,
NEG1-, or
NEG2-CFTR were added to the cis solution.
Unless otherwise noted, the PKA catalytic subunit was present at a
concentration of 50 units/ml in the cis solution. Single
channel currents were recorded with an Axopatch 200A patch clamp unit
(Axon Instruments). The currents were sampled at 1-2.5 ms/point.
Single channel data analyses were performed with pClamp and TIPS software.
 |
RESULTS |
Activity of CFTR Channels Lacking the NEG1 or NEG2
Sequence--
Examination of the primary amino acid sequence of CFTR
revealed two regions with high proportion of negatively charged
residues in the R domain, amino acids 725-733 (NEG1) and amino acids
817-838 (NEG2) (Fig. 1A). The
NEG2 sequence is highly conserved across species (Table
I). To investigate the roles of NEG1 and
NEG2 in CFTR function, these regions were deleted from CFTR. The
resulting
NEG1- and
NEG2-CFTR proteins were transiently expressed
in HEK 293 cells. Membrane vesicles containing CFTR proteins were
isolated and subjected to SDS-PAGE. Like wt-CFTR, both
NEG1- and
NEG2-CFTR are present both in the core glycosylated (band B) and the
fully glycosylated form (band C) (Fig. 1B). The PKA
dependence of the
NEG1-CFTR channel is similar to wt-CFTR (Fig.
1C). No channel activity is observed in the absence of PKA,
and the open probability (Po) of the
NEG1-CFTR channel in the presence of PKA and ATP is similar to
wt-CFTR. In contrast, the
NEG2-CFTR channel opens without PKA (Fig.
1C, right). The "constitutive" activity of
the
NEG2-CFTR channel is unlikely to be due to the endogenous
phosphorylation of the
NEG2-CFTR protein, since protein phosphatase
2A, which decreases activity of the wt-CFTR opened by PKA and ATP (18), has no effect on the
NEG2-CFTR channel (n = 4).
Moreover, addition of PKA up to 200 units/ml, four times the
concentration required to fully activate wt-CFTR (18), does not
increase the open probability of the
NEG2-CFTR channel (Fig.
2). Although the conductance properties of
NEG2-CFTR are similar to those of wild type CFTR (25), its open
probability is much less and cannot be increased with PKA (wt-CFTR
Po = 0.254 ± 0.024, n = 11;
NEG2-CFTR, Po = 0.061 ± 0.015 without PKA and 0.053 ± 0.016, with PKA, n = 8).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 1.
Properties of CFTR with the NEG1 or NEG2
sequence deleted. A, amino acid sequences of
NEG1 and NEG2. B, autoradiograms illustrating in
vitro phosphorylation of wt-, NEG1-, and NEG2-CFTR by PKA in
the presence of [ -32P]ATP. Both the core (band
B) and fully glycosylated (band C) forms of all three
CFTR molecules are phosphorylated. Identical amounts of protein (7.5 µg) were loaded in each lane. C, single channel currents
of wt-, NEG1-, and NEG2-CFTR separately incorporated into the
lipid bilayer. While the activity of wt- (left) and
NEG1-CFTR (middle) absolutely require PKA in the
cis-intracellular solution, the NEG2-CFTR channel opens
without PKA phosphorylation (right). Furthermore, activity
of the NEG2-CFTR channel does not change with PKA phosphorylation
(right).
|
|

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 2.
Diary plot of open probability of the
NEG-2-CFTR channel. Recording begins with
channel stimulated with 50 units/ml PKA and 2 mM ATP on the
cis (intracellular) side. At the arrow, the
amount of PKA was increased to 100 units/ml, and at the second
arrow, to 200 units/ml. After mixing of the additions in the
solution, open probability of the channel did not change. This plot is
representative of three other experiments.
|
|
The failure of the
NEG2-CFTR channel to respond to PKA does not
result from inability of the channel to be phosphorylated, an in
vitro assay using [
-32P]ATP shows comparable
phosphorylation of wt-CFTR and
NEG2-CFTR (Fig. 1B).
Densitometry readings for this gel were: wt-CFTR, Band C, 1063 units,
Band B, 818 units;
NEG2-CFTR, Band C, 1000 units, Band B, 1145 units. However, since expression of
NEG2-CFTR in vesicles was
slightly less than wt-CFTR, on Western blot, values for phosphorylated
protein normalized to the amount of CFTR present were slightly higher
for the
NEG2-CFTR. Densitometry units of radioactive phosphate per
densitometry unit of ECL-labeled CFTR on Western blot for identical
amounts of vesicles were as follows: for wt-CFTR, Band C, 1.3, Band B,
1.16; for
NEG2-CFTR, Band C, 1.58, Band B, 2.38. In a second
experiment, the values were: wt-CFTR, Band C, 1.15, Band B, 0.99; for
NEG2-CFTR, Band C, 1.62, Band B, 2.08. Thus,
NEG2-CFTR was at
least as well phosphorylated as the wt-CFTR under these conditions. The
apparent molecular weight of the phosphorylated
NEG-2 CFTR protein
is less than that of the wild type protein or the
NEG1-CFTR
(apparent Mr 169,000 for wild type-CFTR
Band C versus 160,000 for the
NEG1-CFTR Band C
versus Mr 155,000 for the
NEG2-CFTR Band C). The apparent reduction in molecular weight with
deleting these negatively charged sequences is greater than can be
accounted for by the mass of the amino acids alone. This difference
probably results from the deletion of substantial negative charges
along with the sequence, since disproportion of acidic amino acids,
especially when concentrated in a short sequence, is well known as a
cause of anomalously high molecular weight determinations in SDS-PAGE
(26-28).
The
NEG2-CFTR channel still contains all 10 consensus PKA
phosphorylation sites. Riordan and co-workers (29, 30) showed that even
wt-CFTR with all 10 consensus PKA sites mutated increases its
Po in response to PKA, presumably by
phosphorylation of a weak consensus sequence at Ser753.
Elimination of PKA responsiveness is therefore an unusual property of
the
NEG2-CFTR channel. Since the
NEG2-CFTR channel exhibited reduced Po, it is possible that removal of the
NEG2 sequence also alters the stimulatory function of the R domain on
the CFTR channel. To test this possibility, the following experiments
were performed.
Structural Properties of the NEG2 Sequence--
NEG2 is predicted
to have high
-helical content by several secondary structure
prediction algorithms (23, 24). Molecular modeling of the NEG2 sequence
as an
-helix reveals a long negatively charged stripe circling the
helix, paralleled by two hydrophobic patches (Fig.
3A). To distinguish the effect
of bulk negative charge from that of a specific structural motif due to
this putative helical conformation, several sequence variant peptides
were designed with different predicted helical propensities (Table
II). To retain the negative charge but
disrupt the helix, we synthesized a scrambled NEG2 peptide (s-NEG2)
containing the same amino acids but designed to disrupt the
-helical
content; and in a second variant, we inserted a proline residue into
the sequence to disrupt the helical structure (p-NEG2). To
reduce the negative charge, but retain the helical structure, four
aspartic acid residues were replaced with asparagines, and two glutamic
acid residues were replaced with glutamines, as well as substituting
serine for the native cysteine residue (Cys832) to avoid
disulfide cross-linking of the peptide and replacing the native
methionine (Met837) with norleucine to avoid oxidation. The
resulting peptide was designated h-NEG2i for helical NEG2-inert. The
h-NEG2i peptide has net negative charge of
3, but is predicted to
have strong helical propensity (Table II). An attempt to replace all of
the aspartic acid and glutamic acid residues with their cognate amides resulted in an insoluble peptide. In addition, we obtained an inert
NEG2 variant, NEG2i, with the cysteine to serine and methionine to
norleucine substitutions, to assure that the structural changes we
observed in h-NEG2i were not the result of these substitutions.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 3.
Structure of wt NEG2 peptide and CD
spectroscopy of NEG2 peptide analogues. A, space
filling model of the predicted -helical structure of the NEG2
peptide. The negatively charged Glu and Asp residues are colored
purple, the hydrophoblic residues Leu, Ile, and Phe are
orange, and Lys, light blue. The remaining
residues are gray. B-E, circular dichroism
spectra of NEG2i (pink), h-NEG2i (blue), s-NEG2
(light blue), p-NEG2 (red), and NEG2
(green) at 0, 33, 50, and 66% TFE in water at pH 6.7. F and G, mean residue molar ellipticity plots at
193 and 222 nm for the peptides as a function of TFE. Percent helicity
was estimated from the band intensities using the maximum helical
values of Chen et al. (32).
|
|
Circular dichroism spectra obtained in aqueous solution of increasing
concentrations of trifluoroethanol (TFE, 0-66%) were used to assess
the helical propensities of these peptides (Fig. 3, panels
B-E). There was little or no helical tendency of the p-NEG2 or s-NEG2 peptides in the presence or absence of TFE as demonstrated by the lack of characteristic positive and negative
-helical bands at 193 and 222 nm, respectively (Fig. 3, panels F and G). Instead the large negative bands at 200 nm
suggest predominantly random coil structures for these peptides (31).
The NEG2 and NEG2i peptides demonstrate relatively little helicity in
aqueous solution, however, with increasing TFE concentration, the
helical content steadily increases as shown by the increase in the
characteristic helical bands at 193 and 222 nm. Interestingly, h-NEG2i
has clear helical tendency in the absence of TFE, which can be further
enhanced by TFE addition (Fig. 3, F and G). Mean
residue molar ellipticity plots at 193 and 222 nm for these peptides as
a function of TFE concentration are given in Fig. 3, F and
G, as well as estimates of percent helicity (32). These
plots clearly indicate that h-NEG2i is significantly more helical than
NEG2 or NEG2i and that s-NEG2 and p-NEG2 almost completely lack helical
structures. The different helical propensities between NEG2 and s-NEG2
were also confirmed by two-dimensional NOESY proton NMR spectroscopy.
Effect of Exogenous NEG2 and Its Congeners on CFTR Channel
Activity--
To test whether the NEG2 region is responsible for both
stimulatory and inhibitory interactions between the R domain and other domains of CFTR, the wild type NEG2 peptide was added to the
cis-intracellular side of a single CFTR channel captured in
the planar lipid bilayer (Fig. 4). The
diary plot of Po as a function of time shows the activity of a single wt-CFTR channel during the course of the experiment (Fig. 4). After peptide addition (at
arrows), there are periods of intense stimulation that last
4-8 min, often followed by return to the basal level of activity
observed before peptide addition. In the example shown, activity
reverted to baseline levels 4-8 min after addition of NEG2 peptide at
concentrations 2.2 and 4.4 µM, but at 8.8 µM, stimulation persisted until a still higher
concentration was added, at which time the channel closed. At higher
concentrations, NEG2 produces an almost complete inhibition of the
channel, where only a flickery 3 pS conductance is observed. During
stimulation, the open probability more than doubled and more
transitions were observed between the open and closed states (Fig. 4).
In 10 of 12 experiments in which a peptide concentration
0.44
µM was achieved, a stimulatory response was observed. For the two experiments for which it was not, one channel was inhibited upon initial peptide addition at a concentration of 4.4 µM and no stimulation was observed, and another channel
did not display stimulation. Statistically significant increases in
channel open probability are documented for NEG2 concentrations of 4.4 and 8.8 µM, and increased activity, with
p = 0.09, was observed at 2.2 µM NEG2.
Profound inhibition, comparable with that shown in the example, was
observed in five channels exposed to NEG2 peptide at concentrations
4.4 µM. However, in five other channels treated with
NEG2 peptide at a concentration
4.4 µM, inhibition did
not occur, even at concentrations up to 26.4 µM. For some
of these experiments, the channel may not have survived long enough in the bilayer following addition of peptide to be confident of lack of
inhibition. Nevertheless, at the highest concentrations of peptide
tested, 13.2 and 26.4 µM, statistically significant
inhibition was achieved when all channel recordings are considered.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 4.
Stimulation and inhibition of wt-CFTR channel
by the exogenous NEG2 peptide. Diary plot (open probability
versus time) of a wt-CFTR channel reconstituted into lipid
bilayer membrane, illustrating the effect of the NEG2 peptide on
channel activity. The cis-intracellular solution contained 2 mM ATP and 50 units PKA/ml. Arrows indicate the
time when the peptides were added to the recording solution. The
concentration of NEG2 is indicated above the plot.
Representative single channel currents are shown at 80 mV,
illustrating the stimulatory and inhibitory effects of the NEG2 peptide
on wt-CFTR. This diary plot is from one of 12 experiments with the
wt-CFTR channel. Stimulation was observed in 10 of the 12, and
inhibition, in 5 of 10 in which the channel survived to be tested at
concentrations 4.4 µM. For stimulation, eight paired
experiments were performed at 4.4 µM NEG2, for which
baseline Po was 0.234 ± 0.023 and
stimulated Po was 0.340 ± 0.032 (p = 0.0097). Statistically significant stimulation of
channel activity was also observed in paired experiments for
concentrations of 8.8 µM (n = 6, p = 0.017). Due to the sporadic nature of channel
inhibition by the NEG2 peptide, statistically significant inhibitory
effects were only observed at concentrations of 13.2 µM
(n = 9, Po at baseline 18.8 ± 1.6%, and with 13.2 µM NEG 2, 4.5 ± 0.9%,
p < 0.0001) and 26.4 µM
(n = 5, p < 0.0001).
|
|
Because inhibition did not occur with every experiment when the NEG2
peptide was added to the wt-CFTR channel, we speculated that there
might be competition from the endogenous NEG2 sequence for the binding
sites, and the endogenous sequence might have the advantage of
presentation and proximity. We therefore tested the
NEG-2-CFTR
channel for its ability to undergo stimulation or inhibition by the
exogenous NEG2 peptide. The NEG2 peptide at concentrations 2.2 to 4.4 µM significantly stimulates the
NEG2-CFTR channel
activity, but at higher concentrations, ranging from 2.2 to 13.2 µM, the channel is markedly inhibited (Fig.
5). The NEG2-peptide-induced increase in
NEG2-CFTR channel activity results almost entirely from an increase
in channel openings, from 2.14 ± 0.42 openings/s to 3.94 ± 1.04 openings/s after application of 2.2 µM NEG2, whereas the reduction of channel activity at higher NEG2 peptide concentrations is due to a combination of decrease in channel open lifetime and decrease in channel open events. Inhibition of channel activity occurred in seven of eight experiments in the absence of PKA, and in
all three experiments performed in its presence.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 5.
Stimulation and inhibition of NEG-2-CFTR
channel by NEG2 peptide. A, sample traces of channel
activity in the absence and presence of 2.2 µM NEG2
peptide, with PKA in the cis chamber. These data are
representative of a total of nine experiments, in which
Po increased from 0.072 ± 0.01 in the
control recordings to 0.121 ± 0.02 in the presence of 2.2 µM NEG2 peptide (p < 0.015). Significant
stimulation was also observed at 4.4 µM NEG2
(p = 0.025, n = 9). B, diary
plot of a representative experiment in which increasing concentrations
of NEG2 peptide were added to the cis (intracellular) side
of the channel. Each data point represents the averaged
Po calculated from a complete file consisting of
16 episodes of test pulses to 80 mV (10 s duration) from a holding
potential of 0 mV. The interval between each test pulse was 10 s
at 0 mV. The channel activities at 0 mV were not included in the
calculation of Po. This diary plot is taken from
an experiment performed without PKA present in the cis
solution. When PKA was absent from the system, NEG2-CFTR activity
was inhibited in eight of nine experiments at an average concentration
of 4.3 µM NEG2 peptide. The control
Po was 0.09 ± 0.017, and
Po in the presence of NEG2 peptide was
0.022 ± 0.005 (p = 0.0001, n = 9). When PKA was present (50 units/ml), the NEG2-CFTR channel was
inhibited in three of three experiments at an average concentration of
12.5 µM NEG2 peptide.
|
|
To elucidate the mechanism responsible for the increase in
Po at the lower peptide concentrations, the
gating kinetics of wt-CFTR without peptide and during stimulation by
NEG2 peptide were analyzed. The open time distributions of the wt-CFTR
did not change during peptide stimulation, as both control (without NEG2 peptide) and peptide-stimulated channels had an open lifetime of
~120 ms (Fig. 6A). Thus, the
increase in Po is not due to a change in the
closing rate of the channel. However, the closed time distribution for
the stimulated channel is clearly shifted to the left compared with the
control channel (Fig. 6, B and C). There are
three components to the closed state, a fast
(tc1), an intermediate
(tc2), and a long (tc3)
closed component. Following peptide stimulation, the intermediate
closed time was reduced significantly, from 459 to 105 ms
(p < 0.005). The long closed time was also shortened,
but because of the variability in the measurements (and their paucity
in the stimulated condition), this did not achieve statistical
significance. However, there were significantly fewer episodes in the
long closed time category in the presence of the NEG2 peptide. Thus,
the channel opening rate has increased in the presence of the NEG2
peptide, and this appears to account for the increase in
Po of the channel (Fig. 6D). This
mechanism is similar to what we, and others, observe for phosphorylated
R domain protein (amino acids 588-855 or 645-834) when it stimulates
the wt-CFTR channel (18, 19).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 6.
Kinetic analysis of CFTR channels stimulated
by NEG2 peptide. A-C show histograms of open and closed
events of the wt-CFTR channel at 80 mV, generated under control
conditions (left) and after addition of 4.4 µM
NEG2 peptide to the cis-solution (right). The
open time histograms (A) contain a single exponential
component with a time constant of 124 ms (control) and 105 ms
(peptide-stimulated) (top), values not
significantly different from one another. The closed time histograms
(B) contain a fast component and multiple slow components
(middle). The fast component is probably due to closings
within a burst (33). Therefore, to better identify the closed times
between bursts, a delimiter of tc = 40 ms was
set at the nadir between the fast and intermediate closed times
(arrow) to generate the closed-burst duration histograms
(C). The solid lines represent the fit according
to a double exponential equation: y = P2*exp[t-a2-exp(t-a2)] + P3*exp[t-a3-exp(t-a3)],
where a2 = log tc2,
a3 = log tc3,
P2 = probability of the intermediate closed
component, and P3 = probability of the long
closed component. The best fit parameters are P2 = 0.811, tc2 = 459 ms, P3 = 0.189, tc3 = 2494 ms (control);
P2 = 0.957, tc2 = 105 ms,
P3 = 0.043, tc3 = 1652 ms
(peptide-stimulated). Changes in Po and
tc2 of the wt-CFTR channel in paired
experiments, before and after addition of 4.4 µM wt-NEG2
peptide is shown in D.
|
|
The s-NEG2 peptide has no stimulatory effect on the wt-CFTR channel,
but exhibits inhibition on the wt-CFTR channel (Fig. 7A). In paired experiments,
the wt-CFTR channel has an average Po of
0.266 ± 0.034 (n = 6) under control conditions of
2 mM ATP and 50 units/ml PKA in the intracellular solution.
With the addition of as little as 0.44 µM s-NEG2 peptide,
the Po was reduced by 70%, and with 2.2 µM s-NEG2, the inhibition was 80% (Fig. 7A). The NEG2 peptide with a proline residue inserted in the sequence to
disrupt the helical conformation, p-NEG2, also produced significant channel inhibition (60% at 11 µM) (Fig. 7B).
Inhibition of wt-CFTR has also been reported with the NEG1 peptide
(which carries a total negative charge of
6) by other investigators
(33). Thus, it is likely that charge interactions contribute to the
inhibitory effects of the exogenous peptides on the CFTR channel.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 7.
Maintaining the negative charge, but
disrupting the -helical content of NEG2
peptide results in inhibition without stimulation of CFTR channel
function. A, representative single channel current traces
from a wt-CFTR channel, illustrating the inhibitory effects of s-NEG2.
Data from 6 paired experiments with s-NEG2 are summarized in the
bottom panel. Po = 0.266 ± 0.034, control; 0.051 ± 0.010, +s-NEG2 (p < 0.005). B, various concentrations of p-NEG2 peptide all
inhibited the wt-CFTR channel, without stimulatory effects. Summary of
changes in Po from five paired experiments:
Po = 0.235 ± 0.029, control; 0.194 ± 0.043, +2.2 µM p-NEG2 (p = NS);
0.108 ± 0.023, +11 µM p-NEG2 (p < 0.02).
|
|
To further dissect the stimulatory and inhibitory effects of the NEG2
sequence, we synthesized another peptide, h-NEG2i, in which negative
charge was reduced from
9 to
3 (Table I). As shown in Fig.
3C, the h-NEG2i peptide exhibits higher propensity of
-helical structure in aqueous solution. At the single channel level,
h-NEG2i gave persistent concentration-dependent stimulation of the wt-CFTR without inhibitory activity (Fig.
8). With the addition of 3.6 µM h-NEG2i peptide to the wt-CFTR channel, the channel
open probability increased from 0.228 ± 0.040 to 0.459 ± 0.044 (n = 5 paired experiments) (Fig. 8). The
mechanism of stimulation, like that of wt-NEG2, was not due to an
increase in mean open life time but through the reduction of closed
time of the channel. The number of open events per second was 2.43 ± 1.05 in the control state, but increased to 4.75 ± 0.79 in the presence of hNEG2i (p < 0.01, n = 5).
Unlike the other constructs of NEG2 peptide, h-NEG2i has no inhibitory
effect on wt-CFTR at concentrations as high as 16.5 µM.
The overall effects of the various NEG2 peptides on the wt-CFTR channel
are summarized in Table II.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 8.
Increasing the
-helical content and decreasing the negative charge
of NEG2 peptide result in persistent activation without inhibition of
the CFTR channel. A, representative single channel current
traces are plotted for wt-CFTR at 80 mV testing potential before
(Control) and after the addition of 0.66 µM
h-NEG2i (+h-NEG2i) to the cis-solution.
Persistent activation of the CFTR channel was observed at
concentrations ranging from 0.33 to 11.2 µM h-NEG2i.
B, summary of data from five paired experiments,
demonstrating that the average Po increased from
0.228 ± 0.040 to 0.459 ± 0.044 (n = 5, p < 0.01) with the addition of 3.3 µM
h-NEG2i. C, mean open lifetime of wt-CFTR channel does not
change as a result of h-NEG2i stimulation: o = 151.7 ± 25.2 ms, control; 184.2 ± 22.1, +3.3
µM h-NEG2 (p = NS).
|
|
 |
DISCUSSION |
The R domain of CFTR contains two negatively charged regions,
amino acids 725-733 (NEG1) and amino acids 817-838 (NEG2) which reside in close proximity to two PKA phosphorylation sites,
Ser737 and Ser813, that are used in
vivo (9). One amino acid substitution, noted in a patient with CF,
is reported in the CF Mutation Consortium data base in the NEG1 region
(E725K). Three mutations are reported in the NEG2 region (E822K, E826K,
and D836Y), two of which were obtained from patients with cystic
fibrosis (E822K and D836Y). Single channel studies of E822K and E826K
indicate that both mutations result in reduced
Po compared with wt-CFTR (34). Moreover, Cotten and Welsh (35) showed that N-ethylmaleimide modification of a cysteine residue in the NEG2 region (C832) produced irreversible stimulation of PKA-phosphorylated CFTR channel activity. The NEG2 region is highly conserved among species. Taken together, these data
indicate the importance of this portion of the R domain for the
regulation of the CFTR channel. Our data demonstrate that the NEG2
region of CFTR can both stimulate and inhibit chloride channel
function. When this region is deleted from CFTR, the resultant channel
opens without PKA, indicating loss of inhibitory function, but the
Po never achieves that of wt-CFTR, and does not
increase when phosphorylated with PKA, indicating a loss of stimulatory function. In support of a dual action for the NEG2 sequence, addition of the NEG2 sequence as a synthetic peptide to the intracellular side
of the CFTR channel results in stimulation of channel openings at lower
concentrations, but inhibition of channel activity at higher concentrations.
Stimulatory and inhibitory activities can be separated by sequence
modifications. Inhibition alone is evident with peptides designed to
retain the negative charge but disrupt the helical tendencies.
Conversely, stimulation occurs with a peptide designed to retain and
enhance the helical structure of the sequence, but to reduce the
negative charge. Molecular modeling reveals an amphipathic feature of
the NEG2 sequence, i.e. the negatively charged residues mostly line up as a barber-pole stripe on the
-helix. The
surrounding residues are mostly hydrophobic. We speculate that the NEG2
sequence, presented in different ways, could interact with CFTR at
different sites to either stimulate or inhibit channel openings. Which
function the NEG2 sequence performs might be determined by how it is
presented in the context of the intact molecule, which could be
entrained, at least in part, by the phosphorylation state of the R
domain. In this model, phosphorylated R domain favors presentation of the hydrophobic stripe of the helical conformation of NEG2 to the
stimulatory site, whereas the unphosphorylated R domain favors access
of the negative charge in NEG2 to an inhibitory site. Since the
mechanism of increasing channel activity appears to be, both for NEG2
and for h-NEG2i, mainly by increasing the number of channel openings,
we speculate that the stimulatory activity might result from peptide
binding increasing either binding or hydrolysis of ATP, probably at the
first nucleotide-binding domain, which is often assigned the role of
channel opening (36).
When the exogenous NEG2 peptide is added to the intracellular side of
the wt-CFTR channel, it could interact with either the stimulatory site
or the inhibitory site, and it may compete with the endogenous sequence
for access to these sites. The degree and duration of stimulation or
inhibition by exogenous peptide will depend on the on and off rates at
the stimulatory site and the inhibitory site, the effective
concentration of the relevant structural form of the peptide, and
competition from endogenous sequences (either the NEG2 sequence itself,
or sequences at other sites) at those two sites. When the channel is
closed, as it is most of the time even in the phosphorylated state
(since the Po is only about 30%), the
endogenous site for inhibition may often be occupied by the endogenous
NEG2 sequence, and thus binding of the exogenous peptide is favored at
the stimulatory site. However, as stimulation increases, the inhibitory
site may become more available, and eventually binding occurs at this
site, and the channel is inhibited.
Naren and co-workers (37) reported that a sequence in the
NH2 terminus of CFTR interacts with sequences in the
proximal end of the R domain to increase CFTR channel activity. This
work, taken together with the work reported here, is consistent with our earlier studies of segments of the R domain which inhibit channel
function (21). Two segments, one containing amino acids 588-805 and
the other, amino acids 672-855, proved inhibitory. The first segment
may inhibit channel activity by interacting with the stimulatory
NH2-terminal sequence in CFTR, preventing it from
interacting with its target in the R domain, thereby preventing channel
stimulation. The second inhibitory segment contains the NEG2 sequence,
and probably inhibits channel openings by presenting NEG2 to its
inhibitory site. It is intriguing that the binding portion of the
NH2 terminus, which stimulates channel activity, appears to
be a helical segment of the protein with one negatively charged face,
and its activity is abrogated by reducing the negative charges in this
segment (38). This observation reinforces the concept that negatively
charged sequences may exert profound regulatory influence on channel activity.
A recent study by Baldursson et al. (39) found that deletion
of amino acids 760-783 in the R domain resulted in CFTR channel activity in the absence of PKA phosphorylation; however, deletion of
amino acids 784 to 835, which includes most of the NEG2 sequence, did
not allow the channel to open without phosphorylation. It may be that
the two deletion mutants delete the NEG2 sequence in whole or in part,
ours (
NEG2(817-838)-CFTR) and that of Baldursson et al.
(39) (
(784-835)-CFTR), assume different conformations compared with
the native CFTR molecule and thus may behave differently in channel
function. Baldursson's (39) construct deletes 33 more amino acids
(amino acids 783-816, including a putative PKC-phosphorylation site
(Ser790)) than our
NEG2-CFTR construct. Since PKC
phosphorylation has an essential role in PKA
phosphorylation-dependent regulation of the CFTR channel
(40), removal of this site may alter channel regulation. The potential
role of PKC phosphorylation on the
(784-835)-CFTR and
(817-838)-CFTR remains to be studied. It is also possible that the
R domain contains more than one inhibitory site, or both identified
segments of R domain sequences (760-783 and 817-838) could act
together to inhibit the unphosphorylated CFTR channel, and the lack of
either one disrupts the inhibitory function of the R domain. King and
Sorscher (41) also identify the COOH-terminal portion of the R domain
(amino acids 723-836, which includes both the putative inhibitory
sequences) as crucial in conferring PKA regulation on the channel.
Future studies to identify the sites of NEG2 interaction within the
CFTR molecule should provide new insights into the regulation of the
CFTR channel. Particularly, understanding the stimulatory interaction
of NEG2 may facilitate the design of therapeutics to stimulate the CFTR
opening to treat patients whose mutant forms of CFTR reach the cell surface.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants RO1 HL/DK 49003 and P30 DK27651 (to P. B. D.), RO1
DK51770 (to J. M.) and grants from the Cystic Fibrosis Foundation
(to J. M., P. B. D., and T. A. G.) and
National Institutes of Health Grant T32 HL07415 (to P. B. D.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence may be addressed: Dept. of Pediatrics, Case
Western Reserve University School of Medicine, 10900 Euclid Ave.,
Cleveland, OH 44106. Tel.: 216-368-4370; E-mail:
pbd@po.cwru.edu.

To whom correspondence may be addressed: Dept. of Physiology
and Biophysics, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes
Lane, Piscataway, NJ 08854. Tel.: 732-235-4494; E-mail:
maj2@umdnj.edu.
Published, JBC Papers in Press, April 11, 2002, DOI 10.1074/jbc.M201661200
 |
ABBREVIATIONS |
The abbreviations used are:
CFTR, cystic
fibrosis transmembrane conductance regulator;
TFE, trifluoroethanol;
EBNA-1, Epstein-Barr virus nuclear antigen-1.
 |
REFERENCES |
| 1.
|
Quinton, P. M.
(1986)
Am. J. Physiol.
251,
C649-C652
|
| 2.
|
Welsh, M. J.,
and Smith, A. E.
(1993)
Cell
73,
1251-1254
|
| 3.
|
Zielenski, J.,
and Tsui, L. C.
(1995)
Annu. Rev. Genet.
29,
777-807
|
| 4.
|
Riordan, J.,
Rommens, J.,
Kerem, B.-S.,
Noa, A.,
Rozmahel, R.,
Grzelczak, Z.,
Zielenski, J.,
Lok, S.,
Plavsic, N.,
Chou, J.-L.,
Drumm, M.,
Iannuzzi, M.,
Collins, F.,
and Tsui, L.-C.
(1989)
Science
245,
1066-1073
|
| 5.
|
Higgens, C. F.
(1992)
Annu. Rev. Cell Biol.
8,
67-113
|
| 6.
|
Bear, C. E., Li, C.,
Kartner, N.,
Bridges, R. J.,
Jensen, T. J.,
Ramjeesingh, M.,
and Riordan, J. R.
(1992)
Cell
68,
809-818
|
| 7.
|
Anderson, M. P.,
Berger, H. A.,
Rich, D. P.,
Gregory, R. J.,
Smith, A. E.,
and Welsh, M. J.
(1991)
Cell
67,
775-784
|
| 8.
|
Ma, J.,
and Davis, P. B.
(1998)
Clin. Chest Med.
19,
459-471
|
| 9.
|
Rich, D. P.,
Berger, H. A.,
Cheng, S. H.,
Travis, S. M.,
Saxena, M.,
Smith, A. E.,
and Welsh, M. J.
(1993)
J. Biol. Chem.
268,
20259-20267
|
| 10.
|
Picciotto, M. R.,
Cohn, J. A.,
Bertuzzi, G.,
Greengard, P.,
and Nairn, A. C.
(1992)
J. Biol. Chem.
267,
12742-12752
|
| 11.
|
Cheng, S. H.,
Rich, D. P.,
Marshall, J.,
Gregory, R. J.,
Welsh, M. J.,
and Smith, A. E.
(1991)
Cell
66,
1027-1036
|
| 12.
|
Tabcharani, J. A.,
Chang, X.-B.,
Riordan, J. R.,
and Hanrahan, J. W.
(1991)
Nature
352,
628-631
|
| 13.
|
Gunderson, K. L.,
and Kopito, R. R.
(1995)
Cell
82,
231-239
|
| 14.
|
Dulhanty, A. M.,
and Riordan, J. R.
(1994)
Biochemistry
22,
4072-4079
|
| 15.
|
Ma, J.
(2000)
News Physiol. Sci.
15,
154-158
|
| 16.
|
Wilkinson, D. J.,
Strong, T. J.,
Mansoura, M. K.,
Woud, D. L.,
Smith, S. S.,
Collins, F.,
and Dawson, D. C.
(1997)
Am. J. Physiol.
273,
L127-L133
|
| 17.
|
Rich, D. P.,
Gregory, R. J.,
Anderson, M. P.,
Manavalan, P.,
Smith, A. E.,
and Welsh, M. J.
(1991)
Science
253,
205-207
|
| 18.
|
Ma, J.,
Zhao, J.,
Drumm, M. L.,
Xie, J.,
and Davis, P. B.
(1997)
J. Biol. Chem.
272,
28133-28141
|
| 19.
|
Winter, M. C.,
and Welsh, M. J.
(1997)
Nature
389,
294-296
|
| 20.
|
Ma, J.,
Tasch, J. E.,
Tao, T.,
Zhao, J.,
Xie, J.,
Drumm, M. L.,
and Davis, P. B.
(1996)
J. Biol. Chem.
271,
7351-7356
|
| 21.
|
Tasch, J. E.,
Zerhusen, B.,
Zhao, J., Ma, J.,
and Davis, P. B.
(1999)
FEBS Lett.
445,
63-68
|
| 22.
|
Xie, J.,
Drumm, M. L., Ma, J.,
and Davis, P. B.
(1995)
J. Biol. Chem.
270,
28084-28091
|
| 23.
|
Geourjon, C.,
and Deleage, G.
(1995)
Comput. Appl. Biosci.
11,
681-684
|
| 24.
|
Rost, B.,
and Sander, C.
(1994)
Proteins
19,
55-72
|
| 25.
|
Tao, T.,
Xie, J.,
Drumm, M. L.,
Zhao, J.,
Davis, P. B.,
and Ma, J.
(1996)
Biophys. J.
70,
743-753
|
| 26.
|
Iakoucheva, L. M.,
Kimzey, A. L.,
Masselon, C. D.,
Smith, R. D.,
Dunker, A. K.,
and Ackerman, E. J.
(2001)
Protein Sci.
10,
1353-1362
|
| 27.
|
Armstrong, D. J.,
and Roman, A.
(1993)
Biochem. Biophys. Res. Commun.
192,
1380-1387
|
| 28.
|
Graceffa, P.,
Jancso, A.,
and Mabuchi, K.
(1992)
Arch. Biochem. Biophys.
297,
46-51
|
| 29.
|
Chang, X. B.,
Tabcharani, J. A.,
Hou, Y. X.,
Jensen, T. J.,
Kartner, N.,
Alon, N.,
Hanrahan, J. W.,
and Riordan, J. R.
(1993)
J. Biol. Chem.
268,
11304-11311
|
| 30.
|
Seibert, F. S.,
Tabcharani, J. A.,
Chang, X. B.,
Dulhanty, A. M.,
Mathews, C.,
Hanrahan, J. W.,
and Riordan, J. R.
(1995)
J. Biol. Chem.
270,
2158-2162
|
| 31.
|
Perczell, A.,
Park, K.,
and Fasman, G. D.
(1992)
Proteins Struct. Funct. Genet.
13,
7-69
|
| 32.
|
Chen, Y.-H.,
Yang, J. T.,
and Chau, K. H.
(1974)
Biochemistry
13,
3350-3359
|
| 33.
|
Ikuma, M.,
Baldursson, O.,
Ostedgaard, L. S.,
and Welsh, M. J.
(1999)
Pediatr. Pulmonol. Suppl.
19,
176 (abstr.)
|
| 34.
|
Vankeerberghen, A.,
Wei, L.,
Jaspers, M.,
Cassiman, J.-J.,
Nilius, B.,
and Cuppens, H.
(1998)
Hum. Mol. Genet.
7,
1761-1769
|
| 35.
|
Cotten, J. F.,
and Welsh, M. J.
(1997)
J. Biol. Chem.
272,
25617-25622
|
| 36.
|
Carson, M. R.,
Travis, S. M.,
and Welsh, M. J.
(1995)
J. Biol. Chem.
270,
1711-1717
|
| 37.
|
Naren, A. P.,
Cormet-Boyaka, E., Fu, J.,
Villain, M.,
Blalock, J. E.,
Quick, M. W.,
and Kirk, K. L.
(1999)
Science
286,
544-548
|
| 38.
|
Fu, J., Ji, H-L.,
Naren, A. P.,
and Kirk, K. L.
(2001)
J. Physiol.
536,
459-470
|
| 39.
|
Baldursson, O.,
Ostedgaard, L. S.,
Rokhlina, T.,
Cotton, J. F.,
and Welsh, M. J.
(2001)
J. Biol. Chem.
276,
1904-1910
|
| 40.
|
Jia, Y.,
Mathew, C. J.,
and Hanrahan, J. W.
(1997)
J. Biol. Chem.
272,
4978-4984
|
| 41.
|
King, S. A.,
and Sorscher, E. J.
(2000)
Biochemistry
39,
9869-9875
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Seavilleklein, N. Amer, A. Evagelidis, F. Chappe, T. Irvine, J. W. Hanrahan, and V. Chappe
PKC phosphorylation modulates PKA-dependent binding of the R domain to other domains of CFTR
Am J Physiol Cell Physiol,
November 1, 2008;
295(5):
C1366 - C1375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Lewarchik, K. W. Peters, J. Qi, and R. A. Frizzell
Regulation of CFTR Trafficking by Its R Domain
J. Biol. Chem.,
October 17, 2008;
283(42):
28401 - 28412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gupta, J. Xie, J. Ma, and P. B. Davis
Intermolecular Interaction Between R Domains of Cystic Fibrosis Transmembrane Conductance Regulator
Am. J. Respir. Cell Mol. Biol.,
February 1, 2004;
30(2):
242 - 248.
[Abstract]
[Full Text]
[PDF]
|
 |
|